{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:34:47Z","timestamp":1787963687074,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T00:00:00Z","timestamp":1672790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001407","name":"Department of Biotechnology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["BT\/PR11105\/MED\/30\/1345\/2014"],"award-info":[{"award-number":["BT\/PR11105\/MED\/30\/1345\/2014"]}],"id":[{"id":"10.13039\/501100001407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We investigated the effect of two dosing regimens of oral iron on iron status and hematological parameters in patients with CKD. In this single center, open label, randomized, active controlled clinical trial, stable adult patients with CKD stage G3\u20134 with percentage transferrin saturation (%TSAT) \u2264\u00a030% and serum ferritin \u2264\u00a0500\u00a0ng\/ml were eligible. Participants were randomized to receive either 100\u00a0mg of ferrous ascorbate once daily (OD group) or 100\u00a0mg of ferrous ascorbate twice daily (BD group, total daily dose 200\u00a0mg). The primary outcome was change in %TSAT between groups over 12\u00a0weeks. The secondary outcomes were changes in other iron status and hematological parameters, serum interleukin-6 (IL-6) and hepcidin. 80 participants were enrolled out of which 76 completed the study. Change in %TSAT was not significantly different between groups (\u03b2\u2009=\u2009\u2212\u00a01.43, 95% CI \u2212\u00a03.99 to 1.12, BD group as reference). The rise in serum ferritin was less in the OD group as compared to BD group (\u03b2\u2009=\u2009\u2212\u00a00.36, 95% CI \u2212\u00a00.61 to \u2212\u00a00.10) whereas MCHC increased in the OD group as compared to decrease in the BD group (\u03b2\u2009=\u20090.37, 95% CI 0.067\u20130.67). These observations need exploration to ascertain the impact of different oral iron dosing strategies in CKD.<\/jats:p>","DOI":"10.1038\/s41598-022-26589-x","type":"journal-article","created":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T10:04:08Z","timestamp":1672826648000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["A randomized trial of once daily versus twice daily dosing of oral iron in CKD"],"prefix":"10.1038","volume":"13","author":[{"given":"Vivek","family":"Sood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kajal","family":"Kamboj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prateek","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpita","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur","family":"Sen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raja","family":"Ramachandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Rathi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harbir Singh","family":"Kohli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishan Lal","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashok Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivek","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivekanand","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,4]]},"reference":[{"key":"26589_CR1","doi-asserted-by":"publisher","first-page":"7692376","DOI":"10.1155\/2020\/7692376","volume":"2020","author":"E Palaka","year":"2020","unstructured":"Palaka, E., Grandy, S., van Haalen, H., McEwan, P. & Darlington, O. The impact of CKD anaemia on patients: incidence, risk factors, and clinical outcomes-A systematic literature review. Int. J. Nephrol. 2020, 7692376. https:\/\/doi.org\/10.1155\/2020\/7692376 (2020).","journal-title":"Int. J. Nephrol."},{"key":"26589_CR2","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12882-020-01746-4","volume":"21","author":"H van Haalen","year":"2020","unstructured":"van Haalen, H., Jackson, J., Spinowitz, B., Milligan, G. & Moon, R. Impact of chronic kidney disease and anemia on health-related quality of life and work productivity: Analysis of multinational real-world data. BMC Nephrol. 21, 88. https:\/\/doi.org\/10.1186\/s12882-020-01746-4 (2020).","journal-title":"BMC Nephrol."},{"key":"26589_CR3","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1681\/ASN.2019020213","volume":"31","author":"EK Batchelor","year":"2020","unstructured":"Batchelor, E. K., Kapitsinou, P., Pergola, P. E., Kovesdy, C. P. & Jalal, D. I. Iron deficiency in chronic kidney disease: Updates on pathophysiology, diagnosis, and treatment. J. Am. Soc. Nephrol. 31, 456\u2013468. https:\/\/doi.org\/10.1681\/ASN.2019020213 (2020).","journal-title":"J. Am. Soc. Nephrol."},{"key":"26589_CR4","doi-asserted-by":"publisher","unstructured":"Chapter 2: Use of iron to treat anemia in CKD. Kidney Int. Suppl. (2011) 2, 292\u2013298. https:\/\/doi.org\/10.1038\/kisup.2012.34 (2012).","DOI":"10.1038\/kisup.2012.34"},{"key":"26589_CR5","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1016\/j.kint.2021.03.020","volume":"99","author":"JL Babitt","year":"2021","unstructured":"Babitt, J. L. et al. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney Int. 99, 1280\u20131295. https:\/\/doi.org\/10.1016\/j.kint.2021.03.020 (2021).","journal-title":"Kidney Int."},{"key":"26589_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/1744-9987.12001","volume":"17","author":"K Tsuchiya","year":"2013","unstructured":"Tsuchiya, K. & Nitta, K. Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther. Apher. Dial. 17, 1\u20138. https:\/\/doi.org\/10.1111\/1744-9987.12001 (2013).","journal-title":"Ther. Apher. Dial."},{"key":"26589_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/nu10091173","author":"N Ueda","year":"2018","unstructured":"Ueda, N. & Takasawa, K. Impact of inflammation on ferritin, hepcidin and the management of iron deficiency anemia in chronic kidney disease. Nutrients https:\/\/doi.org\/10.3390\/nu10091173 (2018).","journal-title":"Nutrients"},{"key":"26589_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/603786","volume":"2013","author":"E Urrechaga","year":"2013","unstructured":"Urrechaga, E., Borque, L. & Escanero, J. F. Biomarkers of hypochromia: The contemporary assessment of iron status and erythropoiesis. Biomed. Res. Int. 2013, 603786. https:\/\/doi.org\/10.1155\/2013\/603786 (2013).","journal-title":"Biomed. Res. Int."},{"key":"26589_CR9","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1182\/blood-2015-05-642223","volume":"126","author":"D Moretti","year":"2015","unstructured":"Moretti, D. et al. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 126, 1981\u20131989. https:\/\/doi.org\/10.1182\/blood-2015-05-642223 (2015).","journal-title":"Blood"},{"key":"26589_CR10","doi-asserted-by":"publisher","unstructured":"Revised recommendations for the measurements of the serum iron in human blood. Iron Panel of the International Committee for Standardization in Haematology. Br. J. Haematol. 75, 615\u2013616. https:\/\/doi.org\/10.1111\/j.1365-2141.1990.tb07808.x (1990).","DOI":"10.1111\/j.1365-2141.1990.tb07808.x"},{"key":"26589_CR11","doi-asserted-by":"publisher","unstructured":"The measurement of total and unsaturated iron-binding capacity in serum. Br. J. Haematol. 38, 281\u2013287. https:\/\/doi.org\/10.1111\/j.1365-2141.1978.tb01044.x (1978).","DOI":"10.1111\/j.1365-2141.1978.tb01044.x"},{"key":"26589_CR12","doi-asserted-by":"publisher","first-page":"e524","DOI":"10.1016\/S2352-3026(17)30182-5","volume":"4","author":"NU Stoffel","year":"2017","unstructured":"Stoffel, N. U. et al. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twice-daily split dosing in iron-depleted women: Two open-label, randomised controlled trials. Lancet Haematol. 4, e524\u2013e533. https:\/\/doi.org\/10.1016\/S2352-3026(17)30182-5 (2017).","journal-title":"Lancet Haematol."},{"key":"26589_CR13","doi-asserted-by":"publisher","first-page":"1681","DOI":"10.2215\/CJN.05990809","volume":"5","author":"IC Macdougall","year":"2010","unstructured":"Macdougall, I. C., Malyszko, J., Hider, R. C. & Bansal, S. S. Current status of the measurement of blood hepcidin levels in chronic kidney disease. Clin. J. Am. Soc. Nephrol. 5, 1681\u20131689. https:\/\/doi.org\/10.2215\/CJN.05990809 (2010).","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"26589_CR14","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1111\/j.1751-553X.2011.01355.x","volume":"34","author":"E Urrechaga","year":"2012","unstructured":"Urrechaga, E., Unceta, M., Borque, L. & Escanero, J. F. Low hemoglobin density potential marker of iron availability. Int. J. Lab. Hematol. 34, 47\u201351. https:\/\/doi.org\/10.1111\/j.1751-553X.2011.01355.x (2012).","journal-title":"Int. J. Lab. Hematol."},{"key":"26589_CR15","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/0021-9681(70)90095-0","volume":"23","author":"PD Robertson","year":"1970","unstructured":"Robertson, P. D. & MacLean, D. W. Iron deficiency without anaemia\u2014The MCHC in screening. J. Chronic. Dis. 23, 191\u2013195. https:\/\/doi.org\/10.1016\/0021-9681(70)90095-0 (1970).","journal-title":"J. Chronic. Dis."},{"key":"26589_CR16","unstructured":"Munster, M. Sysmex SEED The Red Blood Cell Indices, https:\/\/www.sysmex-europe.com\/fileadmin\/media\/f100\/SEED\/Sysmex_SEED_The_Red_Blood_Cell_Indices.pdf (2012)."},{"key":"26589_CR17","unstructured":"Bull, B., Aller, R. & Houwen, B. In Haematology 1996, Educational Programme of the 26th Congress of the International Society of Haematology. (eds Lee, S. H. McArthur, J. R., Wong, J. E. L., Ong, Y. W.) Ch. MCHC-Red Cell Index or Quality Control Parameter? (1996)."},{"key":"26589_CR18","first-page":"93","volume":"6","author":"HL Van","year":"2000","unstructured":"Van, H. L., Schisano, T. & Brace, L. Anemia diagnosis, classification and monitoring using Cell-Dyn technology reviewed for the new millennium. Lab. Hematol. 6, 93\u2013108 (2000).","journal-title":"Lab. Hematol."},{"key":"26589_CR19","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1365-2257.1991.tb00264.x","volume":"13","author":"WN Patton","year":"1991","unstructured":"Patton, W. N., Cave, R. J. & Harris, R. I. A study of changes in red cell volume and haemoglobin concentration during phlebotomy induced iron deficiency and iron repletion using the Technicon H1. Clin. Lab. Haematol. 13, 153\u2013161. https:\/\/doi.org\/10.1111\/j.1365-2257.1991.tb00264.x (1991).","journal-title":"Clin. Lab. Haematol."},{"key":"26589_CR20","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1515\/CCLM.2009.301","volume":"47","author":"E Urrechaga","year":"2009","unstructured":"Urrechaga, E., Borque, L. & Escanero, J. F. Potential utility of the new Sysmex XE 5000 red blood cell extended parameters in the study of disorders of iron metabolism. Clin. Chem. Lab. Med. 47, 1411\u20131416. https:\/\/doi.org\/10.1515\/CCLM.2009.301 (2009).","journal-title":"Clin. Chem. Lab. Med."},{"key":"26589_CR21","doi-asserted-by":"publisher","first-page":"256","DOI":"10.3109\/10408363.2015.1038744","volume":"52","author":"NM Archer","year":"2015","unstructured":"Archer, N. M. & Brugnara, C. Diagnosis of iron-deficient states. Crit. Rev. Clin. Lab. Sci. 52, 256\u2013272. https:\/\/doi.org\/10.3109\/10408363.2015.1038744 (2015).","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"issue":"Suppl 1","key":"26589_CR22","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1111\/ijlh.12500","volume":"38","author":"M Buttarello","year":"2016","unstructured":"Buttarello, M. Laboratory diagnosis of anemia: Are the old and new red cell parameters useful in classification and treatment, how?. Int. J. Lab. Hematol. 38(Suppl 1), 123\u2013132. https:\/\/doi.org\/10.1111\/ijlh.12500 (2016).","journal-title":"Int. J. Lab. Hematol."},{"key":"26589_CR23","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/MOH.0b013e32835f5933","volume":"20","author":"C Brugnara","year":"2013","unstructured":"Brugnara, C. & Mohandas, N. Red cell indices in classification and treatment of anemias: From M.M. Wintrobes\u2019s original 1934 classification to the third millennium. Curr. Opin. Hematol. 20, 222\u2013230. https:\/\/doi.org\/10.1097\/MOH.0b013e32835f5933 (2013).","journal-title":"Curr. Opin. Hematol."},{"key":"26589_CR24","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0140-6736(20)32594-0","volume":"397","author":"SR Pasricha","year":"2021","unstructured":"Pasricha, S. R., Tye-Din, J., Muckenthaler, M. U. & Swinkels, D. W. Iron deficiency. Lancet 397, 233\u2013248. https:\/\/doi.org\/10.1016\/S0140-6736(20)32594-0 (2021).","journal-title":"Lancet"},{"key":"26589_CR25","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1093\/ndt\/gfu201","volume":"29","author":"IC Macdougall","year":"2014","unstructured":"Macdougall, I. C. et al. FIND-CKD: A randomized trial of intravenous ferric carboxymaltose versus oral iron in patients with chronic kidney disease and iron deficiency anaemia. Nephrol. Dial. Transplant. 29, 2075\u20132084. https:\/\/doi.org\/10.1093\/ndt\/gfu201 (2014).","journal-title":"Nephrol. Dial. Transplant."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26589-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26589-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26589-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T11:36:31Z","timestamp":1672832191000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-022-26589-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,4]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["26589"],"URL":"https:\/\/doi.org\/10.1038\/s41598-022-26589-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,4]]},"assertion":[{"value":"31 July 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VJ has research grants from Baxter, GSK and reports Consultancy and Advisory Board honoraria from Baxter Healthcare, and AstraZeneca, outside the published work. All other authors reported no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"141"}}